Neal Shore, MD, FACS, explains the treatment regimen he would have chosen for the patient with mCRPC in the presented case, and what factors he uses to inform treatment decision-making.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.